@article{6724c086ae27447e984e40448b031d40,
title = "Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies",
keywords = "benign prostatic enlargement, benign prostatic hyperplasia, LUTS, male patients, mirabegron, overactive bladder, URINARY-TRACT SYMPTOMS, BENIGN PROSTATIC HYPERPLASIA, QUALITY-OF-LIFE, DOUBLE-BLIND, BETA(3)-ADRENOCEPTOR AGONIST, OUTLET OBSTRUCTION, 3-ADRENOCEPTOR AGONIST, MEN, POPULATION, IMPACT",
author = "Andrea Tubaro and Batista, {Jose E.} and Nitti, {Victor W.} and Sender Herschorn and Chapple, {Christopher R.} and Blauwet, {Mary Beth} and Emad Siddiqui and Moses Huang and Matthias Oelke",
year = "2017",
month = jun,
doi = "10.1177/1756287217702797",
language = "English",
volume = "9",
pages = "137--154",
journal = "Therapeutic Advances in Urology",
issn = "1756-2872",
publisher = "SAGE Publications Ltd",
number = "6",
}